Nebenwirkungen · Columvi
Columvi 2.5 mg concentrate for solution for infusion Columvi 10 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 20
HOS-149221 · Präparat HOS-100012
Among the 25 patients who experienced Grade 2 CRS after Columvi, 22 (88.0%) received tocilizumab, 15 (60.0%) received corticosteroids and 14 (56.0%) received both tocilizumab and corticosteroids. Ten patients (40.0%) received oxygen. All 6 patients (24.0%) with Grade 3 or 4 CRS received a single vasopressor.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T13:00:00Z · SHA-256 2c5f4e2a70d7830059221b97eb832e6bb8ef846ec2df0243e5154b9f1ae1a38f · Passage 1b8a0230c6aea1168419881e17e688d21043a1d4e0cae50ab718017ef5fada74 · Zeichen 18722–19033 im Abschnitt